State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL) - consensus report from the Intercepting Blood Cancers Workshop Committee

Sep 23, 2026

Uploaded by Mabel

A panel of international experts convened at the Intercepting Blood Cancers Workshops in March 2023 and March 2024 to address diagnostic challenges, underlying pathophysiology, and potential therapeutic approaches for precursor malignant hematology conditions. The report summarizes sessions focused on monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL), covering MBL biology, clinical implications, progression and transformation from indolent to aggressive disease, and opportunities for early intervention in early-stage, asymptomatic CLL, with consensus management recommendations and research goals.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

INTRODUCTION

Workshop aims and topic tracks

Focus on MBL/CLL themes

Blood Cancer [Journal](Journal www.nature.com/bcj)[ www.nature.com/bcj](Journal www.nature.com/bcj) MEETING REPORT OPEN State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee Christine E. Ryan 1,21, Inhye E. Ahn 1,21, Aswin Sekar1, Andrew Rawstron2, Julia Almeida 3,4, Iñaki Martin-Subero 5, Erin M. Parry1, Miguel Alcoceba4,6, Dinis P. Calado7, Alberto Orfao 3,4, Anton W. Langerak 8, Hendrik Veelken 9, Petra Langerbeins 10, Deborah M. Stephens 11, Sameer A. Parikh 12, Carsten U. Niemann 13, Sandrine Roulland14, Kostas Stamatopoulos 15, Susan L. Slager 12,16, Tait Shanafelt17,22, Paolo Ghia 18,19,22, Jessica Okosun 20,22 and Matthew S. Davids 1,22 ✉ © The Author(s) 2025 | | In March 2023 and 2024, a panel of international experts convened at the ﬁrst and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL) . We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for | | | --- | --- | --- | | | | | | | | | | | | | | | | | | therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals. | | | | | Blood Cancer Journal (2025)15:148; [https://doi.org/10.1038/s41408-025-01341-6](https://doi.org/10.1038/s41408-025-01341-6) | | | | | | INTRODUCTION Over 2 meetings held in March 2023 (Madrid, Spain) and March 2024 (Lisbon, Portugal), the Intercepting Blood Cancers (IBC) Workshop brought together ~75 experts in hematologic malignancies, including clinicians, clinical scientists, translational laboratory researchers, epidemiologists, representatives from the United States Food and Drug Administration (FDA), National Cancer Institute, and patient group representatives from the Leukemia and Lymphoma Society (LLS) . The primary aims of these workshops were to: (1) describe current knowledge of blood cancer precursors and how these might foster early clinical intervention; (2) discuss ongoing clinical studies and any available data from these on interception modalities for early-stage blood cancers; (3) share knowledge and clinical insights between blood cancer disciplines and therapy areas, and (4) plan for publication and dissemination of consensus ﬁndings from discussions across each of the key topic tracks. These included: (A) lymphoma, chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL); (B) Multiple myeloma, smoldering myeloma and monoclonal gammopathy of unknown signiﬁcance (MGUS); and (C) Clonal hematopoiesis of indeterminate potential, clonal cytopenia of undetermined signiﬁcance, Myelodysplastic syndromes and acute myeloid leukemia. Here, we highlight the key discussion points and international expert panel consensus from one of the key topic tracks: MBL/CLL. Similar summary publications for the remaining two key topics of MGUS/myeloma and myeloid precursor conditions will be reported separately. We focus this review on four broad themes that were discussed at the meetings, incorporating data from several key presentations and related discussions (Table 1): the biology of MBL, clinical implications of MBL, progression of MBLand transformation from indolent CLL to aggressive disease, and opportunities for early interception in early stage, asymptomatic CLL. We provide consensus recommendations based on the presentations and discussions during the IBC Workshops, while 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2Leeds Teach

FAQs

What is the purpose of the Intercepting Blood Cancers Workshops in this report?

The workshops bring together experts to review current knowledge of blood cancer precursors, discuss ongoing clinical studies and data for early intervention, share cross-disciplinary insights, and plan publication of consensus findings.

Which main content areas does the consensus report cover for MBL/CLL?

It highlights four areas: biology of MBL, clinical implications of MBL, progression including transformation from indolent CLL to aggressive disease, and opportunities for early therapeutic interception in early-stage, asymptomatic CLL.

Does the report include recommendations for management and research?

Yes. It outlines key consensus management recommendations and research goals based on presentations and discussions during the workshops.

Sep 23, 2026

Uploaded by Mabel